Backgrounds: Colorectal cancer is an important contributor to cancer morbidity and mortality. Given that many older adult patients often have concomitant diseases and impairments in organ function, they are at increased risk for chemotherapy toxicity. Therefore, it is important to identify prognostic factors in older patients undergoing chemotherapy. Methods: We performed a retrospective chart review of colorectal cancer patients treated at Nagoya Memorial Hospital between 2012 and 2017 and selected those who received chemotherapy for metastatic colon cancer. Overall survival was calculated from the beginning of chemotherapy until death or the most recent follow-up date. We used the Kaplan-Meier method to plot survival curves and performed a statistical comparison using a log-rank test. In addition, multivariate analysis was performed using stepwise Cox proportional hazards models. Finally, a comprehensive geriatric assessment was conducted for older patients. The chart review was approved by the ethics committee of Nagoya Memorial Hospital. Results: The overall survival of metastatic colon cancer patients was not markedly different between patients aged < 65 years (N = 17) and those aged ≥ 65 years of age (N = 37). Neither lesion site nor the RAS status affected survival, whereas the usage of three kinds of cytotoxic agents prolonged longevity. In a multivariate analysis of patients ≥ 65 years of age, the only independent prognostic factor for survival was the functional capacity, as measured by the Tokyo Metropolitan Institute of Gerontology (TMIG) index of competence. Conclusions: A combination of the comprehensive geriatric assessment and TMIG index was useful for predicting the longevity in patients with metastatic colon cancer ≥ 65 years of age.
KeywordsMetastatic Colon CancerChemotherapyComprehensive Geriatric AssessmentTMIG Index of Competence
Arnold, M., Sierra, M.S., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2017) Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. Gut, 66, 683-691. https://doi.org/10.1136/gutjnl-2015-310912
Yamazaki, K., Nagase, M., Tanigawa, H., et al. (2016) Randamized Phase III Study of Bevacizumab plus FOLFIRI and Bevacizumab plus mFOLFOX6 as First-Line Treatment for Patients with Metastatic Colorectal Cancer (WJOG4407G). Annals of Oncology, 27, 1539-1546. https://doi.org/10.1093/annonc/mdw206
Van Custem, E., Lenz, H.J., Kohne, C.H., et al. (2015) Fluorouracil, Leucovorin, and Irinotecan plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. Journal of Clinical Oncology, 33, 692-700. https://doi.org/10.1200/JCO.2014.59.4812
Douillard, J.Y., Siena, S., Cassidy, J., et al. (2014) Final Results from PRIME: A Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer. Annals of Oncology, 25, 1346-1355. https://doi.org/10.1093/annonc/mdu141
Loupakis, F., Cremolini, C., Masi, G., et al. (2014) Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. The New England Journal of Medicine, 371, 1609-1618. https://doi.org/10.1056/NEJMoa1403108
Mahipal, A. and Grothey, A. (2016) Role of Biologics in First-Line Treatment of Colorectal Cancer. Journal of Oncology Practice, 12, 1219-1228. https://doi.org/10.1200/JOP.2016.018382
Tournigand, C., Andre, T., Achille, E., et al. (2004) FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Clinical Oncology, 22, 229-237. https://doi.org/10.1200/JCO.2004.05.113
Chibaudel, B., Bonnetain, F., Tournigand, C., et al. (2011) Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Cchemotherapy for Metastatic Colorectal Cancer: A GERCOR Study. Oncologist, 16, 1228-1238. https://doi.org/10.1634/theoncologist.2011-0039
De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F. and Tejpar, S. (2011) KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies in Metastatic Colorectal Cancer. The Lancet Oncology, 12, 594-603. https://doi.org/10.1016/S1470-2045(10)70209-6
The Cancer Genome Atlas Network (2012) Comprehensive Molecular Characterization of Human Colon and Rectal Cancer. Nature, 487, 330-337. https://doi.org/10.1038/nature11252
Richman, S.D., Seymour, M.T., Chambers, P., et al. (2009) KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated with Poor Prognosis but Do Not Preclude Benefit from Oxaliplatin or Irinotecan: Results from the MRC FOCUS Trial. Journal of Clinical Oncology, 27, 5931-5937. https://doi.org/10.1200/JCO.2009.22.4295 https://www.researchgate.net/publication/38062622
Venderbosch, S., Nagtegaal, I.D., Maughan, T.S., et al. (2014) Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 20, 5322-5330. https://doi.org/10.1158/1078-0432.CCR-14-0332
Andre, T., de Gramont, A., Vernerey, D., et al. (2015) Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. Journal of Clinical Oncology, 33, 4176-4187. https://doi.org/10.1200/JCO.2015.63.4238
Weiss, J.M., Pfau, P.R., O’Connor, E.S., et al. (2011) Mortality by Stage for Right- versus Left-Sided Colon Cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare Data. Journal of Clinical Oncology, 29, 4401-4409. https://doi.org/10.1200/JCO.2011.36.4414
Brule, S.Y., Jonker, D.J., Karapetis, C.S., et al. (2015) Location of Colon Cancer (Right-Sided Versus Left-Sided) as a Prognostic Factor and a Predictor of Benefit from Cetuximab in NCIC CO.17. European Journal of Cancer, 51, 1405-1414. https://doi.org/10.1016/j.ejca.2015.03.015
Boeckx, N., Koukakis, R., Op de Beeck, L., et al. (2017) Primary Tumor Sidedness Has an Impact on Prognosis and Treatment Outcome in Metastatic Colorectal Cancer: Results from Two Randomized First-Line Panitumumab Studies. Annals of Oncology, 28, 1862-1868. https://doi.org/10.1093/annonc/mdx119
Holch, J.W., Ricard, I., Stintzing, S., Modest, D.P. and Heinemann, V. (2017) The Relevance of Primary Tumor Location in Patients with Metastatic Colorectal Cancer: A Meta-Analysis of First-Line Clinical Trials. European Journal of Cancer, 70, 87-98. https://doi.org/10.1016/j.ejca.2016.10.007
Hurria, A., Togawa, K., Mohile, S.G., et al. (2011) Predicting Chemotherapy Toxicity in Older Adults with Cancer: A Prospective Multicenter Study. Journal of Clinical Oncology, 29, 3457-3465. https://doi.org/10.1200/JCO.2011.34.7625
Hall, P.S., Lord, S.R., Collinson, M, et al. (2017) A Randomised Phase II Trial and Feasibility Study of Palliative Chemotherapy in Frail or Elderly Patients with Advanced Gastroesophageal Cancer (321GO). British Journal of Cancer, 116, 472-478. https://doi.org/10.1038/bjc.2016.442
Extermann, M. and Hurria, A. (2007) Comprehensive Geriatric Assessment for Older Patients with Cancer. Journal of Clinical Oncology, 25, 1824-1831. https://doi.org/10.1200/JCO.2007.10.6559
Lawton, M.P. and Brody, E.M. (1969) Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living. The Gerontologist, 9, 179-186. https://doi.org/10.1093/geront/9.3_Part_1.179
Koyano, W., Hashimoto, M., Fukawa, T., Shibata, H. and Gunji, A. (1993) Functional Capacity of the Elderly: Measurement by the TMIG Index of Competitive. Japanese Journal of Public Health, 40, 468-474.
Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute, 92, 205-216. https://doi.org/10.1093/jnci/92.3.205
Kanda, Y. (2013) Investigation of the Freely-Available Easy-to-Use Software “EZR” (Easy R) for Medical Statistics. Bone Marrow Transplantation, 48, 452-458. https://doi.org/10.1038/bmt.2012.244